LivaNova PLC - Ordinary Shares (LIVN) Covered Calls
LivaNova PLC is a global medical technology company focused on providing solutions for cardiopulmonary and neuromodulation therapies. The company is a leader in heart-lung machines and oxygenators, as well as VNS Therapy for drug-resistant epilepsy and treatment-resistant depression. LivaNova aims to improve patient outcomes through device innovation and digital health platforms.
You can sell covered calls on LivaNova PLC - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for LIVN (prices last updated Tue 4:16 PM ET):
| LivaNova PLC - Ordinary Shares (LIVN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 64.53 | -1.28 | 25.82 | 69.50 | 986K | - | 3.6 |
| Covered Calls For LivaNova PLC - Ordinary Shares (LIVN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 65 | 1.60 | 67.90 | -4.3% | -62.8% | |
| Jun 18 | 65 | 2.95 | 66.55 | -2.3% | -14.2% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
LivaNova PLC (LIVN) operates in two primary segments: Cardiopulmonary and Neuromodulation. In the Cardiopulmonary segment, the company is a world leader in the design and production of heart-lung machines and oxygenators, essential for open-heart surgery. Its flagship Essenz Perfusion System is a major growth driver, offering advanced data integration and clinical precision. The Neuromodulation segment centers on VNS (Vagus Nerve Stimulation) Therapy, a proprietary treatment for patients with drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD).
As of April 2026, the company has successfully addressed prior reimbursement hurdles. Effective January 1, 2026, the U.S. Centers for Medicare & Medicaid Services (CMS) significantly increased provider reimbursement for VNS Therapy procedures, which has accelerated patient access. LivaNova also recently secured FDA approval for its cloud-based digital health platform, which provides clinicians with deeper data insights for managing epilepsy patients throughout their treatment journey.
Competitive Landscape
LivaNova competes in high-stakes medical device markets characterized by long regulatory cycles and significant R&D requirements. Its primary competitive advantage lies in its dominant share of the heart-lung machine market and its specialized niche in neuromodulation. The company competes for clinical adoption and hospital purchasing contracts based on patient outcomes, device longevity, and ease of use.
- Medtronic plc: The largest competitor in the broader neuromodulation and cardiovascular space, offering a wide range of competing stimulators and surgical tools.
- Boston Scientific Corporation: A major rival in neuromodulation and interventional cardiology, with a focus on deep brain stimulation and spinal cord stimulation.
- Abbott Laboratories: Competes across several cardiovascular and neuromodulation categories, leveraging a massive global distribution network.
- Edwards Lifesciences Corporation: A focused competitor in the structural heart and critical care monitoring segments.
- Integra LifeSciences Holdings Corp.: A peer in the neurosurgery and regenerative medicine markets, often competing for space in the same hospital surgical suites.
Strategic Outlook and Innovation
LivaNova’s strategic outlook for 2026 is defined by the commercial launch of its "aura6000" system for Obstructive Sleep Apnea (OSA). Management has pivoted toward this high-growth market, positioning aura6000 as a differentiated, patient-friendly alternative to CPAP machines. The company has guided for 6.0% to 7.0% constant-currency revenue growth for the full year 2026, supported by the Essenz upgrade cycle and the favorable CMS reimbursement environment.
Innovation is increasingly focused on "Connected Health." By integrating AI-driven analytics into its VNS systems, LivaNova aims to personalize stimulation parameters to further reduce seizure frequency. The company is also investing in battery longevity and lead design to minimize the need for revision surgeries. With a disciplined approach to capital allocation and a focus on expanding its presence in emerging markets like China and India, LivaNova is transitioning from a period of restructuring into a phase of predictable, high-margin growth.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | SPY covered calls | 1. | CAR covered calls | |
| 2. | NVDA covered calls | 7. | HYG covered calls | 2. | USO covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | CMPX covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | QS covered calls | |
| 5. | TLT covered calls | 10. | EEM covered calls | 5. | NOW covered calls | |
Want more examples? LITE Covered Calls | LKFN Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
